evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,361 questions · 1,518 findings · 352 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 73 · 4.8%GRADE not reported 211 · 13.9%Very low 500 · 32.9%Low 411 · 27.1%Moderate 252 · 16.6%High 71 · 4.7%

Low maternal education (<=6 years of schooling) vs Higher maternal education (>6 years)

Poor oral health-related quality of life (OHRQoL) · Children aged 3-12 years

Lower maternal education was associated with poor OHRQoL (OR 1.12, 95% CI 1.00-1.23; 4 studies; high heterogeneity; CI lower bound at the null; ungraded).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Death (all causes) · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in death (all causes) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Graft loss including death · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in total graft loss (with death) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Low probably leads to higher biopsy‐proven acute rejection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Malignancy · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in all malignancy compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Number needing to change treatment · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in number needing to change treatment compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Diabetes · primary immunosuppression in kidney transplant recipients

Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in lymphoma/PTLD compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Acne/rash · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in acne/rash compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients

Low probably leads to lower hypercholesterolaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Anaemia · primary immunosuppression in kidney transplant recipients

Low may leads to lower anaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Thrombocytopenia · primary immunosuppression in kidney transplant recipients

Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Populations in countries with a lower Human Development Index (high category, HDI <0.800) vs Populations in countries with a higher Human Development Index (very high, HDI >=0.800)

Caries experience (mean DMFT) · Adults aged 19-60 years

Pooled caries experience (DMFT) was similar in very-high-HDI and high-HDI countries, and meta-regression found no significant association between national HDI and DMFT; ungraded observational evidence with very high heterogeneity.

3 findings from 1 review

Populations with low socioeconomic status (>=22.4% of the population with low SES) vs Populations with higher socioeconomic status (<22.4% of the population with low SES)

Caries experience (mean DMFT) · Adults aged 19-60 years

Populations with a higher proportion of people with low socioeconomic status had higher caries experience (pooled DMFT 15.99 vs 5.50), and meta-regression associated low SES with higher DMFT (about 10.35 more DMFT per unit; p=0.050); ungraded observational evidence.

5 findings from 1 review
Show 2 more findings